SELLAS Life Sciences Group, Inc. $SLS Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 33.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 345,052 shares of the company’s stock after selling 173,943 shares during the quarter. GSA Capital Partners LLP’s holdings in SELLAS Life Sciences Group were worth $1,301,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Larson Financial Group LLC acquired a new position in SELLAS Life Sciences Group in the 4th quarter worth about $26,000. ProShare Advisors LLC raised its holdings in SELLAS Life Sciences Group by 31.5% in the 4th quarter. ProShare Advisors LLC now owns 22,638 shares of the company’s stock worth $85,000 after purchasing an additional 5,417 shares during the period. World Investment Advisors acquired a new position in SELLAS Life Sciences Group in the 4th quarter worth about $166,000. Money Concepts Capital Corp acquired a new position in SELLAS Life Sciences Group in the 4th quarter worth about $40,000. Finally, EWA LLC acquired a new position in SELLAS Life Sciences Group in the 4th quarter worth about $48,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

Analyst Upgrades and Downgrades

SLS has been the subject of a number of analyst reports. Maxim Group upped their price target on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Price Performance

Shares of SELLAS Life Sciences Group stock opened at $8.97 on Thursday. The business has a 50 day simple moving average of $5.20 and a two-hundred day simple moving average of $3.87. SELLAS Life Sciences Group, Inc. has a 12 month low of $1.39 and a 12 month high of $9.10. The stock has a market capitalization of $1.67 billion, a P/E ratio of -39.00 and a beta of 2.24.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.